Skip to main content
    E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $67.10
    -1.90 (-2.75%)

    Market Cap: $16.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Exelixis Inc (EXEL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Exelixis are BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO) and Summit Therapeutics (SMMT). Exelixis trades at 19.3x earnings, against a median of 27.7x for the 3 of these companies with a P/E. By market cap, Exelixis ranks 5th of the 13 companies on this page; Revolution Medicines (RVMD) is the largest at $37.27B.

    Peer Comparison

    EXEL's revenue growth of 10.2% is below the peer median of 50.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Exelixis (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Halozyme Therapeutics Inc (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    Vaxcyte Inc (PCVX)$10.03BN/AN/A0.0%N/A0.0%0.00%
    Peer median$11.37B27.7x15.9x0.0%-11.0%50.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Exelixis, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Halozyme Therapeutics Inc (HALO)
    Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
    HALO competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    Vaxcyte Inc (PCVX)
    Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally.
    PCVX competitors

    Frequently Asked Questions About EXEL

    Who are Exelixis' main competitors?

    The companies most similar to Exelixis include BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Summit Therapeutics (SMMT), Ascendis Pharma AS (ASND) and TG Therapeutics (TGTX), listed from the closest match.

    Who is Exelixis' biggest competitor?

    Revolution Medicines (RVMD) is the largest of the similar companies at $37.27B; BridgeBio Pharma (BBIO) is the closest match by business profile, size, sector and industry.

    How does EXEL stock compare with its competitors?

    EXEL's P/E is 19.3x against a peer median of 27.7x; its P/S is 6.9x against a peer median of 15.9x; its net margin is 35.4% against a peer median of 0.0%.

    Which of Exelixis' competitors pays a higher dividend?

    Exelixis pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Exelixis bigger than its competitors?

    No. Exelixis is 5th by market cap among the 13 companies on this page; the largest is Revolution Medicines (RVMD) at $37.27B.